Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576110 | 0.93 | CCR5 (0.38) | RPS6KB1CCR5KCNH2DRD2HTR2A | |
| SCHEMBL3579316 | 0.92 | SSTR4 (0.41) | KCNH2SSTR4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1097046 | 0.88 | CCR5 (0.37) | RPS6KB1CCR5KCNH2DRD2HTR2A | |
| SCHEMBL1097414 | 0.88 | CCR5 (0.37) | RPS6KB1CCR5KCNH2DRD2HTR2A | |
| SCHEMBL3570472 | 0.85 | SSTR4 (0.38) | KCNH2HTR2ASSTR4SLC6A2SLC6A3 | |
| SCHEMBL4067653 | 0.84 | SSTR4 (0.41) | KCNH2SSTR4SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4093834 | 0.83 | SSTR4 (0.44) | CCR5SSTR4 | |
| SCHEMBL4094876 | 0.83 | SSTR4 (0.44) | CCR5SSTR4 | |
| SCHEMBL4094874 | 0.83 | SSTR4 (0.44) | CCR5SSTR4 | |
| SCHEMBL4106036 | 0.83 | SSTR4 (0.44) | CCR5SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2085383-A1 | PIPERIDINE DERIVATIVES OR SALTS THEREOF | Astellas Pharma Inc. (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | RPS6KB1 3308/4885CCR5 542/4885KCNH2 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.